APRINOIA Therapeutics Inc. (APRI)

APRINOIA Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	7.73	1.22	9.67
Cash & Cash Equivalents	8.39	1.22	9.67
Cash Growth	-	-87.38%	-
Receivables	-	-	0.16
Other Current Assets	1.16	0.59	0.43
Total Current Assets	9.55	1.81	10.26
Property, Plant & Equipment	-	2.15	0.51
Goodwill and Intangibles	-	0.15	0.32
Other Long-Term Assets	-	1.53	1.68
Total Long-Term Assets	-	3.83	2.51
Total Assets	-	5.64	12.77
Accounts Payable	-	8.89	0.43
Current Debt	-	3.57	0.94
Other Current Liabilities	30.52	2.72	2.99
Total Current Liabilities	30.52	15.18	4.36
Long-Term Debt	-	0.04	0.18
Total Long-Term Liabilities	-	0.04	0.18
Total Liabilities	-	15.22	4.54
Total Debt	15.6	3.61	1.12
Debt Growth	-	223.75%	-
Retained Earnings	-	-90.64	-62.41
Comprehensive Income	-	-0.97	-0.49
Shareholders' Equity	-81.39	-75.45	-48.69
Net Cash / Debt	-7.2	-2.39	8.56
Working Capital	-20.96	-13.36	5.89

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).